Department of Internal Medicine I, University Hospital of Würzburg, Oberdürrbacher-Str. 6, 97080 Würzburg, Germany.
J Clin Endocrinol Metab. 2012 Oct;97(10):3426-37. doi: 10.1210/jc.2012-1981. Epub 2012 Aug 1.
The differential diagnosis of diabetes insipidus (DI) is often challenging but essential, because treatment may vary substantially. This article analyzes the database and performance of currently used differential diagnostic tests for DI and discusses future perspectives for diagnostic improvement.
A review of electronic and print data comprising original and review articles retrieved from the PubMed or Cochrane Library database up to January 2012 was conducted. The search term "polyuria polydipsia syndrome" was cross-referenced with underlying forms of disease and associated clinical, diagnostic, and therapeutic MeSH terms. In addition, references from review articles and textbook chapters were screened for papers containing original data. Search results were narrowed to articles containing primary data with a description of criteria for the differential diagnosis of DI.
Fifteen articles on differential diagnosis of DI were identified, mainly consisting of small series of patients, and mostly covering only part of the differential diagnostic spectrum of DI. Test protocols differed, and prospective validation of diagnostic criteria was consistently missing. Inconsistent data were reported on the diagnostic superiority of direct plasma arginine vasopressin determination over the indirect water deprivation test. Both test methods revealed limitations, especially in the differentiation of disorders with a milder phenotype.
The available data demonstrate limitations of current biochemical tests for the differential diagnosis of DI, potentially leading to incorrect diagnosis and treatment. The newly available assay for copeptin, the C terminus of the vasopressin precursor, holds promise for a higher diagnostic specificity and simplification of the differential diagnostic protocol in DI.
尿崩症(DI)的鉴别诊断常常具有挑战性,但却是必不可少的,因为治疗方法可能会有很大差异。本文分析了目前用于 DI 鉴别诊断的测试方法的数据库和性能,并讨论了诊断改进的未来前景。
对电子和印刷数据进行了回顾,包括从 PubMed 或 Cochrane Library 数据库中检索到的截至 2012 年 1 月的原始和综述文章。检索词“多尿多饮综合征”与疾病的潜在形式以及相关的临床、诊断和治疗 MeSH 术语进行了交叉参考。此外,还对综述文章和教科书章节中的参考文献进行了筛选,以查找包含原始数据的论文,这些论文包含 DI 鉴别诊断的标准描述。
共确定了 15 篇关于 DI 鉴别诊断的文章,主要由小系列患者组成,且大多只涵盖了 DI 鉴别诊断谱的一部分。测试方案不同,诊断标准的前瞻性验证也始终缺失。关于直接血浆精氨酸血管加压素测定优于间接水剥夺试验在诊断优势方面的不一致数据也有报道。这两种测试方法都存在局限性,尤其是在区分症状较轻的疾病方面。
现有数据表明,目前用于 DI 鉴别诊断的生化测试方法存在局限性,可能导致诊断和治疗错误。新的血管加压素前体 C 端copeptin 检测方法有望提高诊断的特异性,并简化 DI 鉴别诊断方案。